Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
J.A. Sáez-Nieto, A. Llacer, F. Catalá, A. Fenoll, J. Casal.
Meningitis meningocócica en España (1978-1980). Estudios epidemiológicos, serogrupos y sensibilidad a agentes antimicrobianos.
Rev Sanid Hig Publica, 55 (1981), pp. 831-869
[2.]
E.S. Kabat, H. Kaiser, H. Sikorski.
Preparation of the type-specific polysaccharide of the type I meningococcus and a study of its effectiveness as an antigen in human beings.
J Exp Med, 80 (1945), pp. 299-307
[3.]
E.C. Gotschlich.
Meningococcal serogroup specific polysaccharides.
Developments in Industrial Microbiology, pp. 92-98
[4.]
C.E. Frasch.
Meningococcal vaccines: past, present and future.
Meningococcal disease, pp. 245-283
[5.]
J.A. Gómez, C.M. Ferreiros, M.T. Criado.
Vacunas polisacarídicas antimeningocócicas.
Enf Inf Microbiol Clin, 15 (1997), pp. 347-348
[6.]
J.A. Vázquez.
Enfermedad meningocócica y vacunación: Un nuevo escenario.
Vacunas, 2 (2001), pp. 1-4
[7.]
L. Salleras, A. Domínguez.
Estrategias de vacunación frente al meningococo sel serogrupo C en España.
Vacunas, 2 (2001), pp. 10-17
[8.]
Q. Zhang, R. Laksman, R. Burkinshaw, S. Choo, J. Everard, S. Akhtar.
Primary and booster mucosal immune responses to meningococcal group A and C conjugate and polysaccharide vaccines administered to university students in United Kingdom.
Infect Immun, 69 (2001), pp. 4337-4341
[9.]
PHLS. Meningitis C vaccine to be offered to 20 to 24 years old.
CDR weekly, 2 (2002), pp. 4-5
[10.]
F.A. Wyle, M.S. Artenstein, B.L. Brandt, E.C. Tramont, D.L. Kasper, P.L. Altieri.
Immunologic response of man to serogroup B meningococcal polysaccharide vaccines.
J Infect Dis, 126 (1972), pp. 514-522
[11.]
J.T. Poolman, C. Feron, G. Dequesne, P.A. Denoël, S. Dessoy, K.K Goraj.
Outer membrane vesicles and other options for a meningococcal B vaccine.
pp. 135-149
[12.]
J.W. Tappero, R. Lagos, A.M. Ballestros, B. Plikaytis, D. Williams, J. Dykes.
Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines. A randomized controlled trail in Chile.
JAMA, 281 (1999), pp. 1520-1527
[13.]
E. Rosenqvist.
Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian Group B meningococcal vaccine.
Infect Immun, 63 (1995), pp. 4642-4652
[14.]
W.D. Zollinger, E.E. Moran, S.J. Devi, C.E. Frasch.
Bactericidal antibody responses of juvenile rhesus monkeys immunized with group B Neisseria meningitidis capsular polysaccharide-protein conjugate vaccines.
Infect Immun, 65 (1997), pp. 1053-1060
[15.]
P. Van der Ley, J. Van der Biezen, J.T. Poolman.
Construction of Neisseria meningitidis strains carrying multiple chromosomal copies of the porA gene for use in the production of a multivalent outer membrane vesicle vaccine.
Vaccine, 13 (1995), pp. 401-407
[16.]
K. Cartwright, R. Morris, H. Runke, A. Fox, R. Borrow, N. Begg.
Immunogenicity and reacogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins.
Vaccine, 17 (1999), pp. 2612-2619
[17.]
N.E. Rosenstein, B.A. Perkins, D.S. Stephens, L. Lefkowitz, M.L. Cartter, R. Danila.
The changing epidemiology of meningococcal disease in the United States, 1992-1996.
J Infect Dis, 180 (1999), pp. 1894-1901
[18.]
A. Peterson, B. Kuipers, M. Pelzer, E. Verhagen, R.H. Tiesjema, J. Tommassen.
Monoclonal antibodies against the 70-kilodalton iron-regulated protein of Neisseria meningitidis are bactericidal and strain specific.
Infect Immun, 58 (1999), pp. 3036-3041
[19.]
C. Ferreirós, M.T. Criado.
Influencia de adyuvantes en la capacidad de los anticuerpos anti-Tbps de bloquear la unión de transferrina, la asimilación de hierro y el crecimiento en Neisseria meningiditis.
Enferm Infecc Microbiol Clin, 20 (2002), pp. 316-320
[20.]
H. Tettelin, N.J. Saunders, J. Heidelberg, A.C. Jeffries, K.E. Nelson, J.A. Eisen.
Complete genome sequence of Neisseria meningitidis serogroup B strain MC58.
Science, 287 (2000), pp. 1809-1815
Copyright © 2002. Elsevier España, S.L.. Todos los derechos reservados
